CLAIM CARD
The next high-yield study for Epigenetic clock should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.
Evidence grade: exploratory
Contradiction status: none
Publication: 9e9f3163-3f3b-4c1f-9790-a8b1400b8696
Provenance: Derivation Web chain
Citation Support
source_1Bozack 2023source_2McGee 2024source_3Marinello 2025source_4Petersen 2021source_5Arpawong 2023